SCHEMBL5036685

SCHEMBL5036685

COc1cc(OC)cc(C(=O)NN)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
KDM4E B2RXH2 3/20 0.62
GAA P10253 3/20 0.62
ALDH1A1 P00352 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 4/20 0.52
HTT P42858 2/20 0.51
CYP1A1 P04798 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP1B1 Q16678 1/20 0.51
RECQL P46063 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31148962 0.96 CA1 (0.66) CA1CA2KDM4EGAAALDH1A1
SCHEMBL13527526 0.83 GAA (0.58) KDM4EGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL9637773 0.83 KDM4E (0.63) KDM4EGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL26497795 0.82 CA1 (0.50) CA1CA2KDM4EGAAALDH1A1
SCHEMBL8437113 0.82 KDM4E (0.71) KDM4EGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL29598340 0.81 NPC1 (0.68) CA1CA2KDM4EALDH1A1SMN1; SMN2
SCHEMBL667723 0.81 NPC1 (0.68) CA1CA2KDM4EALDH1A1SMN1; SMN2
SCHEMBL7959771 0.81 PLK1 (0.64) KDM4EGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL6465455 0.81 CA1 (0.64) CA1CA2KDM4EGAAALDH1A1
SCHEMBL15328092 0.80 GAA (0.54) KDM4EGAAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536385-B1 FILTRATION MEMBRANE WITH IMPROVED HYDROPHILICITY BASF SE (DE) 2026-03-04 EP claimed
EP-4486822-B1 PROCESS FOR THE PREPARATION OF A MEMBRANE (M) CONTAINING A SULFONATED POLYARYLENESULFONE POLYMER (SP) BASF SE (DE) 2025-11-26 EP claimed
US-20250158098-A1 PROCESS FOR THE PREPARATION OF A MEMBRANE (M) CONTAINING A SULFONATED POLYARYLENESULFONE POLYMER (SP) BASF SE (DE) 2025-05-15 US claimed
EP-4536385-A1 FILTRATION MEMBRANE WITH IMPROVED HYDROPHILICITY BASF SE (DE) 2025-04-16 EP claimed
EP-4486822-A1 PROCESS FOR THE PREPARATION OF A MEMBRANE (M) CONTAINING A SULFONATED POLYARYLENESULFONE POLYMER (SP) BASF SE (DE) 2025-01-08 EP claimed
US-12110368-B2 Polyarylene ether sulfone BASF SE (DE) 2024-10-08 US claimed
WO-2023237365-A1 FILTRATION MEMBRANE WITH IMPROVED HYDROPHILICITY BASF SE (DE) 2023-12-14 WO claimed
WO-2023161356-A1 PROCESS FOR THE PREPARATION OF A MEMBRANE (M) CONTAINING A SULFONATED POLYARYLENESULFONE POLYMER (SP) BASF SE (DE) 2023-08-31 WO claimed
EP-3850033-B1 POLYARYLENE ETHER SULFONE BASF SE (DE) 2023-05-17 EP claimed
US-20220056216-A1 POLYARYLENE ETHER SULFONE BASF SE (DE) 2022-02-24 US claimed
EP-4536385-B1 FILTRATION MEMBRANE WITH IMPROVED HYDROPHILICITY BASF SE (DE) 2026-03-04 EP disclosed
EP-4486822-B1 PROCESS FOR THE PREPARATION OF A MEMBRANE (M) CONTAINING A SULFONATED POLYARYLENESULFONE POLYMER (SP) BASF SE (DE) 2025-11-26 EP disclosed
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-4370604-B1 THERMOPLASTIC MOLDING COMPOSITION WITH HIGH TEMPERATURE RESISTANCE COMPRISING A POLYPHENYLENE SULFIDE BASF SE (DE) 2025-08-06 EP disclosed
EP-4370605-B1 THERMOPLASTIC MOLDING COMPOSITION WITH HIGH TEMPERATURE RESISTANCE COMPRISING A THERMOTROPIC POLYMER BASF SE (DE) 2025-08-06 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed
US-6291504-B1 POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES DUPONT PHARMACEUTICALS COMPANY 2001-09-18 US disclosed
US-6265426-B1 CENTRAL NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2001-07-24 US disclosed
EP-1070708-A1 Triazole and imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 CA1 2197/4885CA2 615/4885KDM4E 1020/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP CA1 970/4885CA2 258/4885KDM4E 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.